<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">epidemiology</journal-id><journal-title-group><journal-title xml:lang="ru">Эпидемиология и Вакцинопрофилактика</journal-title><trans-title-group xml:lang="en"><trans-title>Epidemiology and Vaccinal Prevention</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2073-3046</issn><issn pub-type="epub">2619-0494</issn><publisher><publisher-name>«Numicom» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.31631/2073-3046-2023-22-5-89-95</article-id><article-id custom-type="elpub" pub-id-type="custom">epidemiology-1882</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ПРАКТИЧЕСКИЕ АСПЕКТЫ ЭПИДЕМИОЛОГИИ И ВАКЦИНОПРОФИЛАКТИКИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>PRACTICAL ASPECTS OF EPIDEMIOLOGY AND VACCINE PREVENTION</subject></subj-group></article-categories><title-group><article-title>Вакцинация пациентов с коморбидными состояниями против пневмококковой, менингококковой инфекций и гриппа и в условиях пандемии COVID-19 – новые аспекты</article-title><trans-title-group xml:lang="en"><trans-title>Vaccination of Patients with Comorbid Conditions against Meningococcal and Pneumococcal Disease and Influenza during the COVID-19 Pandemic – New Aspects</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1382-9403</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Костинов</surname><given-names>М. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Kostinov</surname><given-names>M. P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Михаил Петрович Костинов – чл.-корр РАН, д. м. н., профессор, зав. лабораторией иммунопрофилактики и иммунотерапии аллергических заболеваний, зав. кафедрой эпидемиологии и современных технологий вакцинации</p><p>105064, Москва, Малый Казенный переулок, д.5а. +7 (495) 917-52-64</p></bio><bio xml:lang="en"><p>Mikhail P. Kostinov – Corresponding member of the Russian Academy of Sciences Dr. Sci. (Med.), Professor, Head laboratory of immunoprophylaxis and immunotherapy of allergic diseases, Head Department of Epidemiology and Modern Vaccination Technologies</p><p>5a, Maly Kazenny lane, Moscow, 105064, +7 (495) 917-52-64</p></bio><email xlink:type="simple">monolit.96@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1076-1930</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Машилов</surname><given-names>К. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Mashilov</surname><given-names>K. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кирилл Вадимович Машилов – доцент, к. м. н., старший научный сотрудник лаборатории вакцинопрофилактики и иммунотерапии аллергических заболеваний</p><p>105064, Москва, Малый Казенный переулок, д.5а. тел. +7 (925) 985-14-24</p></bio><bio xml:lang="en"><p>Kirill V. Mashilov – Cand. Sci. (Med.), Associate Professor, Senior Researcher, Laboratory of Vaccine Prevention and Immunotherapy</p><p>5a, Maly Kazenny lane, Moscow, 105064, +7 (925) 985-14-24</p></bio><email xlink:type="simple">k.v.mashilov@yandex.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2688-429X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Костинова</surname><given-names>Т. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Kostinova</surname><given-names>T. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Татьяна Александровна Костинова – врач функциональной диагностики</p><p>Москва, ул. Радио, д.18.,+7 (495) 917-52-64</p></bio><bio xml:lang="en"><p>Tatyana A. Kostinova – doctor of functional diagnostics</p><p>18, st. Radio, Moscow, + 7 (495) 917-52-64</p></bio><email xlink:type="simple">tatiana.kostinova@gmail.com</email><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБНУ «Научно-­исследовательский институт вакцин и сывороток им. И.И. Мечникова» ; ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» МЗ РФ (Сеченовский Университет)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Department of Allergology, I.I. Mechnikov Research Institute of Vaccines and Sera ; Department of Epidemiology and Modern Vaccination Technologies, Sechenov First Moscow State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБНУ «Научно-­исследовательский институт вакцин и сывороток им. И.И. Мечникова»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Department of Allergology, I.I. Mechnikov Research Institute of Vaccines and Sera</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Московский научно-­практический центр борьбы с туберкулезом Департамента Здравоохранения Москвы</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Moscow Scientific and Practical Center for Tuberculosis Control of the Moscow Department of Health</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>10</day><month>11</month><year>2023</year></pub-date><volume>22</volume><issue>5</issue><fpage>89</fpage><lpage>95</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Костинов М.П., Машилов К.В., Костинова Т.А., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Костинов М.П., Машилов К.В., Костинова Т.А.</copyright-holder><copyright-holder xml:lang="en">Kostinov M.P., Mashilov K.V., Kostinova T.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.epidemvac.ru/jour/article/view/1882">https://www.epidemvac.ru/jour/article/view/1882</self-uri><abstract><p>В обзоре рассматривается и подтверждается важная роль вакцинации пациентов с коморбидными состояниями против пневмококковой, менингококковой инфекций и гриппа в условиях пандемии COVID-19. Выделяются два основных механизма влияния профилактической иммунизации на ход борьбы с пандемией; за счет снижения заболеваемости вакциноуправляемыми инфекциями и снижения нагрузки на здравоохранение и за счет прямого влияния вакцин на заражение вирусом SARS-Cov-2 и патогенетические механизмы COVID-19. Также приводится информация об используемых вакцинах и их применении, в частности, в условиях пандемии COVID-19.</p></abstract><trans-abstract xml:lang="en"><p>The review discusses and confirms the important role of vaccination of patients with comorbid conditions against pneumococcus, influenza and meningococcus in the context of the COVID-19 pandemic. There are two main mechanisms of influence of preventive immunization on the course of the fight against the pandemic; by reducing the incidence of preventable infections and reducing the burden on healthcare, and by directly influencing the vaccines used on the infection processes with the SARS-Cov-2 virus and the pathogenetic mechanisms of COVID-19. Information is also provided on the vaccines used and their use, in particular in the context of the COVID-19 pandemic.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>вакцинация</kwd><kwd>коморбидные состояния</kwd><kwd>пневмококк</kwd><kwd>грипп</kwd><kwd>менингококк</kwd><kwd>COVID-19</kwd></kwd-group><kwd-group xml:lang="en"><kwd>vaccination</kwd><kwd>comorbid conditions</kwd><kwd>pneumococcus</kwd><kwd>flu</kwd><kwd>meningococcus</kwd><kwd>COVID-19</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Guidance on routine immunization services during COVID-19 pandemic in the WHO European Region. 2020;1–12. Доступно на: http://www.euro.who.int/pubrequest</mixed-citation><mixed-citation xml:lang="en">Guidance on routine immunization services during COVID-19 pandemic in the WHO European Region. 2020;1–12. Available at: http://www.euro.who.int/pubrequest</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Вакцинопрофилактика пневмококковой инфекции. Федеральные клинические рекомендации. // Министерство здравоохранения Российской Федерации– Москва, 2015 – 24 с. Доступно на: https://www.rosminzdrav.ru/poleznye-resursy/klinicheskie-rekomendatsii-po-vaktsinoprofilaktike-pnevmokokkovoy-infektsii</mixed-citation><mixed-citation xml:lang="en">Vaccine prevention of pneumococcal infection. Federal clinical guidelines. Ministry of Health of the Russian Federation – Moscow, 2015:24 (In Russ.). Available at: https://www.rosminzdrav.ru/poleznye-resursy/klinicheskie-rekomendatsii-po-vaktsinoprofilaktike-pnevmokokkovoy-infektsii</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Руководство по клинической иммунологии в респираторной медицине. Костинов М. П., Чучалин А. Г., ред. (Изд. 2-е, доп.). М.: Группа МДВ, 2018:304.</mixed-citation><mixed-citation xml:lang="en">Guidelines for Clinical Immunology in Respiratory Medicine. Ed: Kostinov M.P., Chuchalin A.G. (2nd, add.). Moscow: MDV Group, 2018:304 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Краткие алгоритмы ведения пациентов на этапе оказания первичной медико-санитарной помощи.Пособие для врачей-терапевтов. Драпкина О. М., ред. М.: 2019:34.</mixed-citation><mixed-citation xml:lang="en">Manual for general practitioners. Brief algorithms for managing patients at the stage of providing primary health care. Ed.: Drapkina O. M. M.: 2019:34 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Протасов А. Д., Жестков А. В., Костинов М. П. и др. Способ формирования иммунологической памяти к антигенам Streptococcus pneumoniae у пациентов с хронической обструктивной болезнью легких. Патент РФ на изобретение №2544168/17.01.2014. Бюл. №7. ,2544168. 2015:6.</mixed-citation><mixed-citation xml:lang="en">Protasov A.D., Zhestkov A.V., Kostinov M.P., et al. Method for formation of immunological memory to antigens of Streptococcus pneumoniae in patients with chronic obstructive pulmonary disease. RF patent for invention No. №2544168/17.01.2014. Bul. №7. 2544168. 2015:6 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Протасов А. Д., Костинов М. П. Способ активации факторов противовирусной защиты у пациентов с хронической обструктивной болезнью легких. Патент на изобретение № 2591809. 2016:8.</mixed-citation><mixed-citation xml:lang="en">Protasov A.D., Kostinov M.P. A method for activating antiviral protection factors in patients with chronic obstructive pulmonary disease. Patent for invention No. 2591809. 2016:8 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Протасов А. Д., Костинов М. П. Способ усиления активности факторов неспецифической защиты у пациентов с хронической обструктивной болезнью легких Патент РФ на изобретение №2600838/27.10.2016. Бюл. №30.</mixed-citation><mixed-citation xml:lang="en">Protasov A.D., Kostinov M.P. A method for enhancing the activity of nonspecific defense factors in patients with chronic obstructive pulmonary disease Patent of the Russian Federation for the invention No. 2600838/27.10.2016. Bull. No. 30 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Костинов М. П., Абабий И. И., Данилов Л. А. и др. Клинико-иммунологическая эффективность вакцинации конъюгированной пневмококковой вакциной детей с компенсированным хроническим тонзиллитом. // Педиатрия им. Г.Н. Сперанского. 2018; 97 (2): 134–139.</mixed-citation><mixed-citation xml:lang="en">Kostinov M.P., Ababiy I.I, Danilov L.A., et al. Clinical and immunological efficacy of conjugated pneumococcal vaccine in children with compensated chronic tonsillitis. Pediatria n.a. G.N. Speransky. 2018; 97 (2): 134–139 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Костинов М.П., Чучалин А.Г. (Ред.) Руководство по клинической иммунологии в респираторной медицине. (Изд. 2-е, доп.). М.: Группа МДВ, 2018:304.</mixed-citation><mixed-citation xml:lang="en">Guidelines for Clinical Immunology in Respiratory Medicine. (Ed. 2nd, add.). Ed.: Kostinov M.P., Chuchalin A.G. Moscow: MDV Group, 2018:304 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Вакцинация против гепатита В, гриппа и краснухи взрослых пациентов с хроническими заболеваниями. Руководство. Костинов М. П., Зверев В. В.,ред. М.: рДВ, 2009:196.</mixed-citation><mixed-citation xml:lang="en">Vaccination against hepatitis B, influenza and rubella in adult patients with chronic diseases. Ed.: Kostinov M.P., Zverev V.V. Management. M.: MDV, 2009:196 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Черданцев А. П., Кусельман А. И., Синицина М. Н. и др. Изучение клинической безопасности вакцинации против гриппа у беременных. // Медицинский альманах. 2011;4:120–122.</mixed-citation><mixed-citation xml:lang="en">Cherdantsev A.P., Kuselman A.I., Sinitsina M.N. Study of the clinical safety of vaccination against influenza in pregnant women. Medical almanac. 2011;4:120–122(In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Зверев В. В., Костинов М. П., Черданцев А. П. и др. Вакцинация беременных против гриппа: Федеральные клинические рекомендации. Н. Новгород, 2015:42.</mixed-citation><mixed-citation xml:lang="en">Zverev V.V., Kostinov M.P., Cherdantsev A.P. Vaccination of pregnant women against influenza: Federal clinical guidelines. N. Novgorod, 2015:42 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Костинов М. П., Черданцев А. П., Сависько А. А. и др. Истинные и ложные реакции на введение вакцины против гриппа у беременных. // Вопросы гинекологии, акушерства и перинатологии. 2011;10(6):44–48.</mixed-citation><mixed-citation xml:lang="en">Kostinov M.P., Cherdantsev A.P., Savisko A.A., et al. True and false reactions to the introduction of influenza vaccine in pregnant women. Issues of gynecology, obstetrics and perinatology. 2011;10(6):44–48 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Черданцев А. П., Костинов М. П., Кусельман А. И. Вакцинация беременных против гриппа и других инфекционных заболеваний. Руководство для врачей (изд. 3-е, доп.). М.: Группа МДВ, 2018:143.</mixed-citation><mixed-citation xml:lang="en">Cherdantsev A.P., Kostinov M.P., Kuselman A.I. Vaccination of pregnant women against influenza and other infectious diseases. A Guide for Physicians (3rd ed., add.). Moscow: MDV Group, 2018:143 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Черданцев А. П., Костинов М. П., Кусельман А. И. Вакцинопрофилактика гриппа у беременных. Руководство для врачей. М.: Группа МДВ, 2014:112.</mixed-citation><mixed-citation xml:lang="en">Cherdantsev A.P., Kostinov M.P., Kuselman A.I. Vaccination of influenza in pregnant women. Guide for doctors. Moscow: MDV Group, 2014:112 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Fink G., Orlova-Fink N., Schindler T. et al. Inactivated trivalent influenza vaccine is associated with lower mortality among Covid-19 patients in Brazil. // BMJ EvidenceBased Medicine 2021;26:192–193.</mixed-citation><mixed-citation xml:lang="en">Fink G., Orlova-Fink N., Schindler T., et al. Inactivated trivalent influenza vaccine is associated with lower mortality among Covid-19 patients in Brazil. BMJ EvidenceBased Medicine 2021;26:192–193</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Conlon A., Ashur C., Washer L., et al. Impact of the influenza vaccine on COVID-19 infection rates and severity. Am J Infect Control. 2021; 49 (2021): 694−700.</mixed-citation><mixed-citation xml:lang="en">Conlon A., Ashur C., Washer L., et al. Impact of the influenza vaccine on COVID-19 infection rates and severity. Am J Infect Control. 2021; 49 (2021): 694−700.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Чебыкина А. В. Андреева Н. П., Петрова Т. И. и др. Новые возможности профилактики гриппа у пациентов с хроническими заболеваниями органов дыхания. Русский медицинский журнал. 2010;24: 1473–1476.</mixed-citation><mixed-citation xml:lang="en">Chebykina A.V. Andreeva N.P., Petrova T.I. New opportunities for influenza prevention in patients with chronic respiratory diseases. Russian medical journal. 2010;24:1473–1476.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Протасов А. Д., Жестков А. В., Костинов М. П. и др. Изменения микробного пейзажа мокроты у пациентов с хронической обструктивной болезнью легких на фоне вакцинации против пневмококка, гемофильной инфекции типа b и гриппа. // Пульмонология. 2012;(5):23–27. https://doi.org/10.18093/0869-0189-2012-0-5-23-27</mixed-citation><mixed-citation xml:lang="en">Protasov A.D., Zhestkov A.V., Kostinov M.P., et al. Changes in sputum bacterial landscape after vaccination against Streptococcus pneumoniae, Haemophilus influenza type b and influenza in patients with chronic obstructive pulmonary disease. Pulmonologiya. 2012;(5):23–27 (In Russ.). https://doi.org/10.18093/0869-0189-2012-0-5-23-27</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Бойцов С.А., Лукьянов М.М., Платонова Е.В., и др. Оценка эффективности вакцинопрофилактики гриппа по данным проспективного контроля у лиц, находящихся под диспансерным наблюдением по поводу болезней системы кровообращения. // Рациональная фармакотерапия в кардиологии. 2016;12(6):703–710. DOI: http://dx.doi.org/10.20996/1819-6446-2016-12-6-703-710</mixed-citation><mixed-citation xml:lang="en">Boytsov S.A., Loukianov M.M., Platonova E.V., et al. Efficiency of Influenza Vaccination in Patients with Circulatory System Diseases under Dispensary Observation in Outpatient Clinics: Prospective Follow-up Monitoring Data. Rational Pharmacotherapy in Cardiology 2016;12(6):703–710 (In Russ). DOI: 10.20996/1819-6446-2016-12-6-703-710</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Remschmidt C., Wichmann O., Harder T., et al. Vaccines for the prevention of seasonal influenza in patients with diabetes: systematic review and meta-analysis. BMC Med. 2015;13:53. Доступно на: https://bmcmedicine.biomedcentral.com/track/pdf/10.1186/s12916-015-0295-6.pdf</mixed-citation><mixed-citation xml:lang="en">Remschmidt C., Wichmann O., Harder T., et al. Vaccines for the prevention of seasonal influenza in patients with diabetes: systematic review and meta-analysis. BMC Med. 2015;13:53. Available at: https://bmcmedicine.biomedcentral.com/track/pdf/10.1186/s12916-015-0295-6.pdf</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Wang IK, Lin CL, Chang YC. Effectiveness of influenza vaccination in elderly diabetic patients: a retrospective cohort study. // Vaccine. 2013;31(4):718−724.</mixed-citation><mixed-citation xml:lang="en">Wang IK, Lin CL, Chang YC. Effectiveness of influenza vaccination in elderly diabetic patients: a retrospective cohort study. Vaccine. 2013;31(4):718−724.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Root-Bernstein, R., Age and Location in Severity of COVID-19 Pathology: Do Lactoferrin and Pneumococcal Vaccination Explain Low Infant Mortality and Regional Differences?. // BioEssays 2020, 42, 2000076.</mixed-citation><mixed-citation xml:lang="en">Root-Bernstein, R., Age and Location in Severity of COVID-19 Pathology: Do Lactoferrin and Pneumococcal Vaccination Explain Low Infant Mortality and Regional Differences?. BioEssays 2020, 42, 2000076.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Root-Bernstein R. Innate receptor activation patterns involving tlr and nlr synergisms in covid-19, ali/ards and sepsis cytokine storms: A review and model making novel predictions and therapeutic suggestions., // International Journal of Molecular Sciences, 2021;22 (4): 1–47</mixed-citation><mixed-citation xml:lang="en">Root-Bernstein R. Innate receptor activation patterns involving tlr and nlr synergisms in covid-19, ali/ards and sepsis cytokine storms: A review and model making novel predictions and therapeutic suggestions., International Journal of Molecular Sciences, 2021;22 (4): 1–47</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Zhu X, Ge Y, Wu T, Zhao K, Chen Y, Wu B, Zhu F, Zhu B, Cui L. Co-infection with respiratory pathogens among COVID-2019 cases. // Virus Res. 2020 Aug;285 198005.</mixed-citation><mixed-citation xml:lang="en">Zhu X, Ge Y, Wu T, Zhao K, Chen Y, Wu B, Zhu F, Zhu B, Cui L. Co-infection with respiratory pathogens among COVID-2019 cases. Virus Res. 2020 Aug;285 198005.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Root-Bernstein R. Possible cross-reactivity between SARS-CoV-2 proteins, CRM197 and proteins in pneumococcal vaccines may protect against symptomatic SARS-CoV-2 disease and death. // Vaccines. 2020 Dec 1;8(4):1–20.</mixed-citation><mixed-citation xml:lang="en">Root-Bernstein R. Possible cross-reactivity between SARS-CoV-2 proteins, CRM197 and proteins in pneumococcal vaccines may protect against symptomatic SARS-CoV-2 disease and death. Vaccines. 2020 Dec 1;8(4):1–20.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Хромова Е. А., Семочкин И. А., Ахматова Э. А. и др. Вакцины против гриппа: влияние на TLRs. Российский иммунологический журнал. Тематический выпуск «Калининградский научный форум». 2016, том 10 (19), № 2 (1) :505–507.</mixed-citation><mixed-citation xml:lang="en">Khromova E.A., Semochkin I.A., Akhmatova E.A. Influenza vaccines: impact on TLRs. Russian immunological journal. Thematic issue «Kaliningrad Scientific Forum». 2016, vol. 10 (19), no. 2 (1): 505–507 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Хромова Е. Е., Семочкин И. А., Ахматова Э. А. и др. Сравнительная активность вакцин против гриппа: влияние на субпопуляционную структуру лимфоцитов. // Журнал микробиологии, эпидемиологии и иммунобиологии. 2016;6:61–65. https://doi.org/10.36233/0372-9311-2016-6-61-65</mixed-citation><mixed-citation xml:lang="en">Chromova E. A., Semochkin L. A., Akhmatova E. A., et al. Comparative activity of influenza vaccines: effect on lymphocyte subpopulation structure Journal of microbiology, epidemiology and immunobiology. 2016; 61–65 (In Russ.). https://doi.org/10.36233/0372-9311-2016-6-61-65</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Kostinov M.P. About the Safety of Adjuvant Vaccines in Pregnant Women: An Expert Opinion. // Int J Pregn &amp; Chi Birth. 2017; 3(2): 00060.</mixed-citation><mixed-citation xml:lang="en">Kostinov MP. About the safety of adjuvant vaccines in pregnant women: an expert opinion. Int J Pregn &amp; Chi Birth. 2017;3(2):242–243(In Russ.). DOI: 10.15406/ipcb.2017.03.00060</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Хромова Е. А., Сходова С. А., Столпникова В. Н. и др. Влияние современных вакцин против гриппа на ключевые эффекторы врожденного и адаптивного иммунитета. Тезисы докладов научно-практической конференции молодых ученых «Актуальные вопросы эпидемиологии, диагностики, лечения и профилактики инфекционных и онкологических заболеваний». Москва, 17–18 апреля 2018:156.</mixed-citation><mixed-citation xml:lang="en">Khromova E.A., Skhodova S.A., Stolpnikova V.N. Influence of modern influenza vaccines on key effectors of innate and adaptive immunity. Abstracts of the scientific-practical conference of young scientists «Topical issues of epidemiology, diagnosis, treatment and prevention of infectious and oncological diseases». Moscow, April 17–18, 2018:156 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Соколова Т. М., Полосков В. В., Шувалов А. Н. Вакцины «Гриппол» и «Ваксигрип» активаторы экспрессии генов системы врожденного иммунитета в клетках острой моноцитарной лейкемии ТНР1. // Евразийский союз ученых. 2016;5(26):61–63.</mixed-citation><mixed-citation xml:lang="en">Sokolova T.M., Poloskov V.V., Shuvalov A.N. Vaccines «Grippol» and «Vaxigrip» activators of gene expression of the innate immunity system in acute monocytic leukemia THP1 cells. Eurasian Union of Scientists. 2016;5(26):61–63 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Prompetchara E., Ketloy C., Palaga T. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. // Asian Pac J Allergy Immunol. 2020; 38(1): 1–9. doi:10.12932/AP-200220-0772</mixed-citation><mixed-citation xml:lang="en">Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol. 2020;38(1):1–9. doi:10.12932/AP-200220-0772</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Костинов М. П. Иммунопатогенные свойства SARS-CoV-2 как основа для выбора патогенетической терапии. Иммунология. 2020;41(1):83–91 DOI: 10.33029/0206-4952-2020-41-1-83-91</mixed-citation><mixed-citation xml:lang="en">Kostinov M.P. Immunopathogenic properties of SARS-CoV-2 as a basis for the choice of pathogenetic therapy. Immunologiya 2020; 41(1):83–93 (In Russ.). DOI: 10.33029/0206-4952-2020-41-1-83-91</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Приоритетная вакцинация респираторных инфекций в период пандемии SARS-COV-2 и после ее завершения. Пособие для врачей. Костинов М. П., Чучалин А. Г., ред. М.: Группа МДВ, 2020:32. ISBN 976-5-906748-16-4.</mixed-citation><mixed-citation xml:lang="en">Priority vaccination for respiratory infections during and after the SARS-COV-2 pandemic. A guide for doctors. Ed.: Kostinov M.P., Chuchalin A.G. Moscow: MDV Group, 2020:32. ISBN 976-5-906748-16-4 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">О состоянии санитарно-эпидемиологического благополучия населения в Российской Федерации в 2019 г.: Государственный доклад. – М.: Федеральная служба по надзору в сфере защиты прав потребителей и благополучия человека, 2020:299.</mixed-citation><mixed-citation xml:lang="en">On the state of sanitary and epidemiological well-being of the population in the Russian Federation in 2019: State report. Moscow: Federal Service for Supervision of Consumer Rights Protection and Human Welfare, 2020:299 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Taha MK, Deghmane AE. Impact of COVID-19 pandemic and the lockdown on invasive meningococcal disease. // BMC Res Notes [Internet]. 2020;13(1):1–6. Available from: https://doi.org/10.1186/s13104-020-05241-9</mixed-citation><mixed-citation xml:lang="en">Taha MK, Deghmane AE. Impact of COVID-19 pandemic and the lockdown on invasive meningococcal disease. BMC Res Notes [Internet]. 2020;13(1):1–6. Available at: https://doi.org/10.1186/s13104-020-05241-9</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Костинов М. П. Вакцинация взрослых – от стратегии к тактике. Руководство для врачей. - М.: Группа МДВ, 2020:248.</mixed-citation><mixed-citation xml:lang="en">Kostinov M.P. Vaccination of adults from strategy to tactics. Guide for doctors. - M.: Group MDV, 2020:248 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Костинов А. М., Костинов М. П. Восприимчивость к SARS-CoV-2 привитых против S. pneumoniae – механизмы неспецифического действия пневмококковой вакцины. // Педиатрия им. Г. Н. Сперанского. - 2020; 99(6):183–189 doi: 10.24110/0031-403X-2020-99-6-183-189</mixed-citation><mixed-citation xml:lang="en">Kostinov A.M. Kostinov, M.P. Susceptibility of people vaccinated against S. pneumoniae to SARS-CoV-2 – mechanisms of non-specific action of pneumococcal vaccine. Pediatria n.a. G.N. Speransky. 2020; 99 (6): 183–189 (In Russ.). doi: 10.24110/0031-403X-2020-99-6-183-189</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Костинов А.М, Костинов М.П., Машилов К.В. Пневмококковые вакцины и COVID-19 – антагонизм. // Медицинский совет. – 2020; 17:66–73 doi: 10.21518/2079-701X-2020-17-66-73</mixed-citation><mixed-citation xml:lang="en">Kostinov A.M., Kostinov M.P., Mashilov C.V. Antagonism between pneumococcal vaccines and COVID-19. Meditsinskiy sovet = Medical Council. 2020;(17):66–73 (In Russ.) https://doi.org/10.21518/2079-701X-2020-17-66-73</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Руководство по вакцинации и иммунотерапии при ЛОР-патологии. Костинов М. П., Абабия И. И., ред. М.: Группа МДВ. 2019:448.</mixed-citation><mixed-citation xml:lang="en">Kostinov M.P., Ababiya I.I. (Ed.) Guidelines for vaccination and immunotherapy in ENT pathology. Moscow: MDV Group. 2019:448 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Протасов А. Д., Жестков А. В., Лаврентьева Н. Е. и др. Эффект комплексной вакцинации против пневмококковой, гемофильной типа b инфекций и гриппа у пациентов с хронической обструктив-ной болезнью легких. // Журнал микробиологии, эпидемиологии и иммунобиологии. 2011;4:80–84.</mixed-citation><mixed-citation xml:lang="en">Protasov A.D., Zhestkov A.V., Lavrentieva N.E. The effect of complex vaccination against pneumococcal, hemophilic type b infections and influenza in patients with chronic obstructive pulmonary disease. Journal of microbiology, epidemiology and immunobiology. 2011;4:80–84(In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Протасов, А. Д., Жестков, А. В., Костинов, М. П. и др. Изменения микробного пейзажа мокроты у пациентов с хронической обструктивной болезнью легких на фоне вакцинации против пневмококка, гемофильной инфекции типа b и гриппа. // Пульмонология. 2012; (5):23–27 https://doi.org/10.18093/0869-0189-2012-0-5-23-27</mixed-citation><mixed-citation xml:lang="en">Protasov A.D., Zhestkov A.V., Kostinov M.P., et al. Changes in sputum bacterial landscape after vaccination against Streptococcus pneumoniae, Haemophilus influenza type b and influenza in patients with chronic obstructive pulmonary disease. Pulmonologiya. 2012;(5):23–27. (In Russ.) https://doi.org/10.18093/0869-0189-2012-0-5-23-27</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Костинов М. П. Новое в клинике, диагностике и вакцинопрофилактике управляемых инфекций. // М., 1997:110.</mixed-citation><mixed-citation xml:lang="en">Kostinov M.P. New in the clinic, diagnostics and vaccination of preventable infections. M., 1997:110 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Костинов М. П., Малеев В. В. Hib-инфекция: вопросы вакцинопрофилактики. // М.: Медицина для всех, 1998:78.</mixed-citation><mixed-citation xml:lang="en">Kostinov M.P., Maleev V.V. Hib infection: issues of vaccination. Moscow: Medicine for everyone, 1998:78 (In Russ.). (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Брико Н. И., Симонова Е. Г., Костинов М. П. и др. ред. Иммунопрофилактика пневмококковых инфекций. Учебно-методическое пособие. // М.: 2013:278.</mixed-citation><mixed-citation xml:lang="en">Briko N.I., Simonova E.G., Kostinov M.P., et al. Immunoprophylaxis of pneumococcal infections. Study guide -. Moscow: 2013:278 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Расширение комплекса лечебно-профилактических мероприятий при бронхиальной астме у детей с применением вакцин ПНЕВМО 23 и Акт-ХИБ. Пособие для врачей. Костинов М. П., ред. // М.: Медицина для всех, 2004:36.</mixed-citation><mixed-citation xml:lang="en">Kostinov M.P. (Ed.) Expansion of the complex of therapeutic and preventive measures for bronchial asthma in children with the use of vaccines PNEUMO 23 and Act-HIB. A guide for doctors. Moscow: Medicine for everyone, 2004:36 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Гаращенко Т. И., Костинов М. П., Ильенко Л. И. и др. Профилактическое и терапевтическое использование гемофильной и пневмококковой вакцин у часто и длительно болеющих детей с рецидивирующими средними отитами. // Вопросы современной педиатрии, 2006;5(5) 24–28.</mixed-citation><mixed-citation xml:lang="en">Garashchenko T.I., Kostinov M.P., Ilienko L.I., et al. Preventive and therapeutic application of Hib and pneumococcal vaccines among children, who are prone to frequent and prolonged recurrent otites media. Current Pediatrics. 2006;5(5):24–28 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Маркелова Е. В., Гущина Я. С., Костинов М. П. и др. Клинико-иммунологический эффект вакцинации «ПНЕВМО 23» детей с атопической бронхиальной астмой. // Журнал микробиологии, эпидемиологии и иммунобиологии. 2005;2:83–85.</mixed-citation><mixed-citation xml:lang="en">Markelova E.V., Gushchina Ya.S., Kostinov M.P., et al. Clinical and immunological effect of vaccination «PNEUMO 23» in children with atopic bronchial asthma. Journal of Microbiology, Epidemiology and Immunobiology. 2005;2:83–85 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Public Health England. Annual flu programme. // Seasonal influenza (flu) is an unpredictable but recurring pressure that the NHS faces every winter. Vaccination offers the best protection. Updated 14 May 2021. https://www.gov.uk/government/collections/annual-flu-programme [accessed 24 May 2021</mixed-citation><mixed-citation xml:lang="en">Public Health England. Annual flu programme. Seasonal influenza (flu) is an unpredictable but recurring pressure that the NHS faces every winter. Vaccination offers the best protection. Updated 14 May 2021. https://www.gov.uk/government/collections/annual-flu-programme [accessed 24 May 2021</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Centers for Disease Control and Prevention. // Interim clinical considerations for use of COVID-19 vaccines currently authorized in the United States. March 2021. Available at https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html [accessed 12 March 2021].</mixed-citation><mixed-citation xml:lang="en">Centers for Disease Control and Prevention. Interim clinical considerations for use of COVID-19 vaccines currently authorized in the United States. March 2021. Available at https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html [accessed 12 March 2021].</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Toback S., Galiza E., Cosgrove C. et al. Safety, Immunogenicity, and Efficacy of a COVID-19 Vaccine (NVX-CoV2373) Co-administered With Seasonal Influenza Vaccines. MedRxiv preprint, journal for submission The Lancet. 2021; Available at https://www.medrxiv.org/content/10.1101/2021.06.09.21258556v1.full.pdf</mixed-citation><mixed-citation xml:lang="en">Toback S., Galiza E., Cosgrove C. et al. Safety, Immunogenicity, and Efficacy of a COVID-19 Vaccine (NVX-CoV2373) Co-administered With Seasonal Influenza Vaccines. MedRxiv preprint, journal for submission The Lanc et. 2021; Available at https://www.medrxiv.org/content/10.1101/2021.06.09.21258556v1.full.pdf</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Федеральное руководство по использованию лекарственных средств (формулярная система). Чучалин А. Г., Яснецов В. В., ред. Вып.XVI. М., 2015:1016.</mixed-citation><mixed-citation xml:lang="en">Federal Guidelines for the Use of Medicines (formulary system). Ed.: Chuchalin A.G., Yasnetsov V.V. Issue XVI. M., 2015:1016(In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Коровкина Е. С., Костинов М. П. Современные конъюгированные вакцины, применяемые для профилактики менингококковой инфекции. // Инфекционные болезни: новости, мнения, обучение. 2018;1:138–45.</mixed-citation><mixed-citation xml:lang="en">Korovkina E.S., Kostinov M.P. Prevention of meningococcal infection with conjugate vaccines. Infectious Diseases: News, Opinions, Training. 2018; 7 (1): 60–8 (In Russ.).</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
